Planning underway for Phase 2 trial of LYT-300 in Fragile X-associated Tremor/Ataxia Syndrome
LYT-300 is also being evaluated in a Phase 2a trial for anxiety disorders, and a Phase 2a in patients.
PureTech Health plc has been awarded $11.4 million (£8.9 million) from the US Department of Defense (DoD) to advance its therapeutic candidate for the potential treatment of neurological and neuropsychiatric disorders.
E-Mail
The UC Davis MIND Institute and the National Fragile X Foundation are working to encourage and accelerate research about the genetic condition with a new registry. The International Fragile X Premutation Registry is welcoming participants worldwide who are interested in taking part in research studies. The registry was created to facilitate and encourage fragile X premutation research around the world, including future medication and non-medication treatment and intervention studies that could positively impact quality of life, said Linda Sorensen, executive director of the National Fragile X Foundation.
The goal is to build a contact list containing a large, diverse group of people interested in contributing to research by taking part in clinical trials and other studies.